Two things decide which benefit pays for a drug: who administers it and how the claim is coded. If a clinician acquires, administers, and bills the drug as part of a service — typically an infusion or in-office injection — it routes to the medical benefit and is billed with a HCPCS J-code or Q-code plus an administration CPT code. If the drug is dispensed to the patient for self-administration (or caregiver administration) at home, it routes to the pharmacy benefit and is billed by National Drug Code (NDC), with no administration line. The two paths carry different prior-authorization departments, different patient cost structures, and — for Medicare — a specific statutory boundary: Part B (medical) versus Part D (pharmacy).
Medicare's medical benefit, Part B, was built around drugs "furnished incident to" a physician's professional service — the statute assumes a clinician draws up and administers the dose. Part D, enacted in 2003 via the Medicare Modernization Act and effective January 1, 2006, was built to cover the much larger universe of self-administered outpatient prescriptions filled at a pharmacy. The Social Security Act's self-administered-drug test (§1861(s)(2)(B)) asks whether a drug is "usually self-administered" by more than half of patients; CMS delegates the actual determination to each Medicare Administrative Contractor (MAC), which is why the same HCPCS code can be Part B-payable in one state's jurisdiction and Part D-only in another's. Commercial payers build an analogous split — a medical drug policy administered by the plan's utilization-management team, and a pharmacy formulary administered by a pharmacy benefit manager (PBM) — but the dividing line and the specific drug list vary by plan and are not standardized the way the Medicare SAD test attempts to be.
This site's self-administered drug (SAD) list tracks 58 drugs across 8 Medicare Administrative Contractor exclusion lists — the closest thing to a codified medical-vs-pharmacy-benefit boundary in Medicare — cross-referenced against 401 unique HCPCS J/Q codes in the 417-drug CareCost catalog.
Four factors distinguish a medical-benefit claim from a pharmacy-benefit claim for the same drug order. None of these is dispositive on its own for a given plan — a commercial payer can build a medical drug policy that departs from the Medicare pattern — but together they are the checklist a biller runs before assuming either benefit applies.
| Factor | Medical benefit | Pharmacy benefit |
|---|---|---|
| Site of care | Physician office, infusion suite, or hospital outpatient department — a clinician acquires and administers the dose (buy-and-bill or white bagging). | Retail, mail-order, or specialty pharmacy dispenses the drug directly to the patient (or a caregiver) for self-administration at home. |
| Coding on the claim | HCPCS J-code or Q-code, billed in the code's defined units, plus an administration CPT code (infusion or injection). JW/JZ waste modifiers apply to single-dose containers. | National Drug Code (NDC), billed by quantity dispensed and days supply. No administration CPT line — the pharmacy's dispensing fee replaces it. |
| Prior authorization | Reviewed by the payer's medical/utilization-management team against ICD-10 diagnosis, site of care, and clinical criteria tied to the J-code. Usually requested by the ordering provider before the drug is acquired. | Reviewed by the PBM against formulary tier, step-therapy rules, and quantity limits tied to the NDC. Usually initiated by the prescriber or the specialty pharmacy before the fill ships. |
| Patient cost path | Typically a medical-plan deductible and coinsurance (for example, Medicare Part B's 20% coinsurance on the ASP-based drug payment). Commonly not subject to accumulator/maximizer adjustment. | Typically a specialty-tier copay or coinsurance under the pharmacy formulary. Often the target of accumulator-adjustment or copay-maximizer programs that decide whether manufacturer copay assistance counts toward the deductible/out-of-pocket max. |
| Who determines the split (Medicare) | Not on the MAC's self-administered drug (SAD) exclusion list for that jurisdiction — presumptively Part B-eligible when a provider administers it. | Listed on the MAC's SAD exclusion list — excluded from Part B and covered instead under Part D. |
For a full walkthrough of the Medicare-specific test and the current MAC-by-MAC exclusion data, see the self-administered drug (SAD) list and the JA/JB route modifier reference, which cover the route-dependent codes that can land on either side depending on how a given dose was actually given.
Ustekinumab (brand name Stelara) is a clean real-world case because the manufacturer sells two formulations of the identical molecule under two different HCPCS codes, and the two codes land on opposite sides of the medical/pharmacy line.
The two codes are mutually exclusive on a claim — billing the IV vial under J3357 or the SC syringe under J3358 is a hard coding error, not a benefit choice. See the full Stelara billing reference for dosing, ICD-10, and biosimilar detail on both formulations.
Route-dependent codes are the case that trips up this checklist most often: some HCPCS codes are payable under either benefit depending on who actually gave the dose, which is why our SAD list flags "route-dependent" status separately from a flat exclusion, and why the JA/JB modifiers exist to tell the payer which route was used on a given claim line.
The medical benefit pays for drugs a clinician acquires, administers, and bills as part of a professional or facility service — the claim carries the drug's HCPCS J-code or Q-code plus an administration CPT code, and the payer's medical-policy team handles prior authorization. The pharmacy benefit pays for drugs dispensed to the patient (retail, mail-order, or specialty pharmacy) and self-administered or caregiver-administered — the claim carries the drug's National Drug Code (NDC) with no administration line, and the payer's pharmacy benefit manager (PBM) handles prior authorization and formulary tiering. The same drug can fall on either side depending on its formulation and how it is given; a growing number of specialty biologics ship in both a provider-administered IV form and a self-injectable form, each billed under a different benefit.
Part B (the medical benefit) covers drugs "furnished incident to" a physician service and administered in a clinical setting; Part D (the pharmacy benefit) covers self-administered outpatient drugs dispensed through a retail or mail-order pharmacy. CMS applies a rule of thumb — is the drug usually self-administered by more than half of patients? — and each Medicare Administrative Contractor (MAC) publishes its own self-administered drug (SAD) exclusion list applying that test to specific HCPCS codes. A code on a MAC's SAD list is excluded from Part B and falls to Part D; a code not on the list is presumptively Part B-eligible when given by a provider. Check the drug's HCPCS code against your MAC's current SAD list before assuming either benefit applies.
A HCPCS J-code (or Q-code) identifies a drug and its billing-unit basis for a medical claim — one code can cover multiple manufacturers, strengths, and package sizes of the same active ingredient. A National Drug Code (NDC) is an 11-digit FDA identifier specific to one manufacturer, strength, and package size, used on pharmacy claims and increasingly required as a secondary identifier on medical claims for drug-specific rebate and utilization tracking. A medical-benefit claim leads with the J-code and units administered; a pharmacy-benefit claim leads with the NDC and quantity dispensed.
Yes. Medical-benefit prior authorization is typically reviewed by the payer's medical or utilization-management team against the diagnosis (ICD-10), site of care, and clinical criteria tied to the J-code — it is usually requested by the ordering provider's office before the drug is acquired. Pharmacy-benefit prior authorization runs through the PBM against the drug's formulary tier, step-therapy requirements, and quantity limits tied to the NDC — it is typically initiated by the prescriber or the dispensing specialty pharmacy before the fill ships. A drug's PA criteria, timeline, and appeal path can differ meaningfully between the two even when the underlying molecule is identical.
Several specialty biologics are manufactured in two formulations of the same molecule: a provider-administered IV or infusion form (billed on the medical benefit under its own J-code) and a self-injectable subcutaneous form (typically billed on the pharmacy benefit, and often excluded from Part B outright on the MAC self-administered drug list). Ustekinumab (Stelara) is a public example — J3358 covers the IV induction vial billed on the medical benefit, while J3357 covers the subcutaneous maintenance syringes, which fall on the MAC self-administered drug list and route to the pharmacy benefit instead. The benefit follows the formulation and route ordered, not the brand name.
Accumulator adjustment programs and copay maximizer programs are pharmacy-benefit cost-management tools that determine whether manufacturer copay assistance counts toward a patient's deductible and out-of-pocket maximum. They apply almost exclusively to pharmacy-benefit specialty-tier drugs billed by NDC; medical-benefit claims paid under a coinsurance structure (for example, Medicare Part B's 20% coinsurance on the ASP-based drug payment) are not typically subject to accumulator or maximizer adjustment, though commercial medical-benefit plan designs vary and should be verified per plan document.
data-asp bindings read from for medical-benefit drugs.All sources are publicly available federal publications, FDA labeling, or paraphrased from trade-association educational materials. The methodology by which we resolve source disagreements is described in the Methodology.